Phase II study to evaluate the efficacy and tolerability of fulvestrant 250mg, 250mg plus 500mg loading regimen and 500mg in postmenopausal women with ER +ve advanced breast cancer progressing or relapsing after previous endocrine therapy

Trial Profile

Phase II study to evaluate the efficacy and tolerability of fulvestrant 250mg, 250mg plus 500mg loading regimen and 500mg in postmenopausal women with ER +ve advanced breast cancer progressing or relapsing after previous endocrine therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms FINDER-II
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2018.
    • 29 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 16 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top